
Please try another search
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.
Name | Age | Since | Title |
---|---|---|---|
Vikram Malik | 60 | 2020 | President & Director |
Marc Forth | 53 | 2019 | Director |
Seongsoo Park | 49 | 2024 | Director |
Rob Bancroft | - | 2025 | President, CEO & Director |
Jost Fischer | 71 | 2017 | Independent Chairman |
Robert J. Palmisano | 80 | 2023 | Independent Director |
Shelley B. Thunen | 71 | 2023 | Independent Director |
Eric G. Carter | 73 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review